Non-Hodgkin’s Lymphomas, Version 4.2014

Abstract

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Advances in the diagnosis and control of lymphomas

“…2,3,5 New approaches have been developed, including immunotherapy, monoclonal antibodies, iMIDs (immunomodulatory drugs), as well as targeted therapy, such as tyrosine kinase inhibitors: 1) Monoclonal antibodies (mAb): mAbs represent the cornerstone of passive immuno-therapy, which involves engineering of B or T cell receptors targeting a desired antigen and infusion into patients with disease.…”

“…International guidelines have been primarily focused on diagnosis and therapeutical recommendations, including all the new methodology applied to these malignancies. 2,3 However, although in Mexico attention to some non-Hodgkin lymphomas salud pública de méxico / vol. 58, no.…”

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study

“…2 These facts should prompt investigations aimed at clarifying whether maintenance after initial R-CHOP or bendamustine-based immunochemotherapy might abrogate the prognostic impact of the MLH1 genotype.…”

“…1,2 In contrast, a limited set of biomarkers is available to predict treatment outcome in patients with this lymphoma. 3,4 The activity of drugs employed for the treatment of FL may be affected by the patient's genetic background.…”

Endoscopic Appearances with a High Probability of Positive Biopsy in Follow-up Endoscopy of Gastric Mucosa-associated Lymphoid Tissue Lymphoma

“…However, the target site or number of biopsies is not mentioned. 16 According to the European Gastro-Intestinal Lymphoma Study consensus report, follow-up endoscopy with biopsy mapping, including a minimum of 10 biopsies from visible lesions and macroscopically normal mucosae should be performed and initial sites of lymphoma involvement should be evaluated. 7 European Society for Medical Oncology guidelines also suggest that sequential evaluation of multiple gastric biopsies is essential to exclude the possibility of significant persistent disease and watch for early epithelial changes, which may be related to gastric carcinoma.…”